

***Fiscal Year 2023 Department of Defense Prostate Cancer Research Program (PCRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Data Science Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT9425-23-PCRP-DSA</p>	<p>Independent investigators at all levels</p>	<ul style="list-style-type: none"> • Supports research where quantitative and analytical approaches, processes, and/or systems are developed and/or used to obtain knowledge and insight from large and/or complex sets of prostate cancer data. • Applications may propose development of a new data science-driven tool or apply an existing tool or method to gather and analyze information from large data sets with the intent of advancing prostate cancer research and patient care relative to the FY23 PCRP Overarching Challenges. • Research efforts must be built upon the logic, concepts, and methods of one or more of the following research areas as they pertain to prostate cancer: <ul style="list-style-type: none"> ○ Analysis of clinically annotated datasets ○ Analysis of -omics data ○ Artificial intelligence and machine learning ○ Bioinformatics ○ Computational biology ○ Digital pathology ○ Epidemiology ○ Medical imaging • <i>Clinical research is allowed but must be retrospective; prospective recruitment of human subjects and/or clinical trials are not allowed.</i> • Presentation of preliminary data is strongly encouraged, but not required. • Each investigator may be named as Principal Investigator (PI) on only one application. • <i>Partnering PI Option:</i> Allows two PIs, termed the Initiating and Partnering PIs, to collaborate on a single application. Collaborations between data scientists and clinicians are highly encouraged. At least one of the submitting or partnering PIs must have expertise in prostate cancer basic and/or clinical research. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1 million (M) for direct costs (plus indirect costs). • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent [LOI]): August 3, 2023 5:00 p.m. Eastern time (ET)</p> <p>Application: August 24, 2023 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Early Investigator Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT9425-23-PCRP-EIRA</p>	<p><i>By March 31, 2024,</i></p> <p>Post-doctoral PIs:</p> <ul style="list-style-type: none"> • Must possess a doctoral degree (or equivalent) • Have 3 years or less of postdoctoral research experience (excluding clinical residency or clinical fellowship training) 	<ul style="list-style-type: none"> • Supports research opportunities focused on prostate cancer for individuals in the early stages of their careers. • PIs must have a designated mentor who is an experienced prostate cancer researcher. • Applications must include a Researcher Development Plan articulating an individualized strategy for acquiring necessary skills, competence, and expertise to complete the project and foster the PI’s career development. • <i>Clinical trials are not allowed.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$300,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 2 years. 	<p>Pre-Application (LOI): August 3, 2023 5:00 p.m. ET</p> <p>Application: August 24, 2023 11:59 p.m. ET</p> <p>Confidential Letters of Recommendation: August 29, 2023 5:00 p.m. ET</p>
<p>Exploration – Hypothesis Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT9425-23-PCRP-EHDA</p>	<p>Investigators at or above the level of post-doctoral fellow (or equivalent)</p>	<ul style="list-style-type: none"> • Supports the exploration of highly innovative, untested, potentially groundbreaking concepts in prostate cancer. • Emphasis is on innovation; the potential impact may be difficult to predict. • Presentation of preliminary data is strongly discouraged. • <i>Clinical trials are not allowed.</i> • <i>Applications proposing studies involving human subjects or specimens must qualify for exempt or expedited status.</i> • Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborators, and their organization(s). 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$100,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 2 years. 	<p>Pre-Application (LOI): June 22, 2023 5:00 p.m. ET</p> <p>Application: July 13, 2023 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Health Disparity Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-PCRP-HDRA</p>	<p><i>Established Investigators:</i></p> <p>Independent investigators at all levels</p> <p><i>New Investigators:</i></p> <p>Investigators that meet the following criteria at the application submission deadline date:</p> <ul style="list-style-type: none"> • Have the freedom to pursue individual aims without formal mentorship • Have not previously received a PCRP Health Disparity Research Award and/or Idea Development Award • Have either completed at least 3 years of post-doctoral training or a fellowship or are within 10 years after completion of a terminal degree (excluding residency or family medical leave) 	<ul style="list-style-type: none"> • Supports research ideas that have the potential to make an important contribution to reducing and ultimately eliminating disparities in prostate cancer incidence, morbidity, and mortality. • Proposed projects are <i>encouraged to address one of the following health disparity focus areas:</i> (1) biological contributors, (2) environmental factors, (3) social and cultural factors, or (4) access to health care. • Proposed projects may include basic, translational, or clinical research, including clinical trials. • Primary emphasis will be placed on the potential impact of the proposed work. • Preliminary data are encouraged, but not required. • Investigators are <i>highly encouraged</i> to engage members of the targeted population or community in the development and implementation of their research project, where appropriate. • Each investigator may be named as PI on only one application. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$900,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (LOI):</p> <p>August 3, 2023 5:00 p.m. ET</p> <p>Application:</p> <p>August 24, 2023 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Idea Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-PCRP-IDA</p>	<p><i>Established Investigators:</i> Independent investigators at all levels</p> <p><i>New Investigators:</i> Investigators that meet the following criteria at the application submission deadline date:</p> <ul style="list-style-type: none"> • Have the freedom to pursue individual aims without formal mentorship • Have not previously received a PCRP Idea Development Award and/or Health Disparity Research Award • Have either completed at least 3 years of post-doctoral training or a fellowship or are within 10 years after completion of terminal degree (excluding residency or family medical leave) 	<ul style="list-style-type: none"> • Supports new ideas that represent innovative, high-risk/high-gain approaches to prostate cancer research and have the potential to make an important contribution to one or more of the FY23 PCRP Overarching Challenges. • Emphasis is equally placed on Innovation and Impact. • Preliminary data are encouraged, but not required. • Clinical trials are not allowed. • Each investigator may be named as PI on only one application. • Multidisciplinary projects are encouraged, and multi-institutional projects are allowed. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$900,000 for direct costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (LOI): June 29, 2023 5:00 p.m. ET</p> <p>Application: July 20, 2023 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Physician Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT9425-23-PCRP-PRA</p>	<p>At the time of application submission, the PI must be either:</p> <ul style="list-style-type: none"> • In the last year of an accredited medical residency or medical fellowship program <p>Or</p> <ul style="list-style-type: none"> • Within 5 years of having initiated a faculty appointment (including Instructor positions) 	<ul style="list-style-type: none"> • Supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research. • PIs must demonstrate a commitment to a career at the forefront of prostate cancer research and clinical practice. • PIs must have a designated mentor with an established research program in prostate cancer. • Applications are strongly encouraged to demonstrate protection of at least 40% of the PI’s time for prostate cancer research (not required to be exclusive to this award). • Applications must include a Researcher Development Plan articulating an individualized strategy for acquiring necessary skills, competence, and expertise to complete the project and foster the PI’s career development. • <i>Clinical trials are not allowed.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$750,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (LOI): August 3, 2023 5:00 p.m. ET</p> <p>Application: August 24, 2023 11:59 p.m. ET</p> <p>Confidential Letters of Recommendation: August 29, 2023 5:00 p.m. ET</p>
<p>Translational Science Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT9425-23-PCRP-TSA</p>	<p>Independent investigators at all levels</p>	<ul style="list-style-type: none"> • Supports advanced translational research that will foster transformation of promising ideas in prostate cancer into clinical applications, ultimately providing a solution to one or more of the FY23 PCRP Overarching Challenges. • Translational research may be defined as an integration of basic science and clinical observations, including a reciprocal flow of ideas and information from bench to bedside and/or bedside to bench. • Supports a broad range of translational studies such as: <ul style="list-style-type: none"> ○ Advanced translation of results from animal studies to applications with human samples/cohorts ○ Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug application submission ○ Correlative studies that are associated with an open/ongoing or completed clinical trial, e.g., projects that utilize biospecimens from clinical trial 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$900,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (LOI): August 3, 2023 5:00 p.m. ET</p> <p>Application: August 24, 2023 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
		<p>to improve clinical management of prostate cancer and/or define new areas of research</p> <ul style="list-style-type: none"> ○ Projects that develop endpoints for clinical trials ○ Analysis of existing data, resources, or clinical tools to inform clinical practice and/or maximize patient-relevant outcomes ○ Small-scale clinical trials with implementation science focus <ul style="list-style-type: none"> ● <i>Preliminary data to support the scientific rationale and feasibility of the research approaches are required.</i> ● The inclusion of additional preliminary data to support the clinical relevance of the idea is strongly encouraged. ● Each investigator may be named as PI on only one application. ● <i>Partnering PI Option:</i> Allows two PIs, termed the Initiating and Partnering PIs, to collaborate on a single application. Collaborations between basic science and clinical researchers are highly encouraged. ● <i>Clinical Trial with Implementation Science Option:</i> Allows for studies proposing small-scale clinical trials that focus on implementation science. Implementation science studies are expected to bridge the gap between research, practice, and policy by building a knowledge base on how interventions, clinical practices/guidelines, tools, and policies can be deployed to targeted populations at the appropriate time and point of need. 		